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Abstract
Background: The progression towards type 2 diabetes depends on the allostatic response of pancreatic beta cells
to synthesise and secrete enough insulin to compensate for insulin resistance. The endocrine pancreas is a plastic
tissue able to expand or regress in response to the requirements imposed by physiological and pathophysiological
states associated to insulin resistance such as pregnancy, obesity or ageing, but the mechanisms mediating beta
cell mass expansion in these scenarios are not well defined. We have recently shown that ob/ob mice with genetic
ablation of PPARg2, a mouse model known as the POKO mouse failed to expand its beta cell mass. This phenotype
contrasted with the appropriate expansion of the beta cell mass observed in their obese littermate ob/ob mice.
Thus, comparison of these models islets particularly at early ages could provide some new insights on early PPARg
dependent transcriptional responses involved in the process of beta cell mass expansion
Results: Here we have investigated PPARg dependent transcriptional responses occurring during the early stages
of beta cell adaptation to insulin resistance in wild type, ob/ob, PPARg2 KO and POKO mice. We have identified
genes known to regulate both the rate of proliferation and the survival signals of beta cells. Moreover we have
also identified new pathways induced in ob/ob islets that remained unchanged in POKO islets, suggesting an
important role for PPARg in maintenance/activation of mechanisms essential for the continued function of the beta
cell.
Conclusions: Our data suggest that the expansion of beta cell mass observed in ob/ob islets is associated with
the activation of an immune response that fails to occur in POKO islets. We have also indentified other PPARg
dependent differentially regulated pathways including cholesterol biosynthesis, apoptosis through TGF-b signaling
and decreased oxidative phosphorylation.
Background
Although the hallmark of obesity associated type 2 dia-
betes (T2D) is the decrease in insulin sensitivity, the
development of hyperglycemia requires the failure of the
allostatic response of the b-cells to respond by produ-
cing enough insulin to overcome the functional defect
in insulin action [1]. One of the strategies the endocrine
pancreas uses to adapt to changes in insulin resistant
requirements associated with different physiological
states, such as pregnancy, obesity, or ageing, is to
expand the b-cell mass. Thus, in all these states insulin
resistance leads to an increased production of insulin to
maintain euglycemia [2]. Despite the increased require-
ments, the majority of individuals remain euglycemic by
adequately increasing their b-cell mass and by adjusting
their stimulated insulin secretion. However, when the
allostatic b-cell adaptation fails, hyperglycemia will
develop. Under conditions of allostatic overload, there is
an association between pregnancy with gestational dia-
betes and obesity and ageing with T2D [3].
In humans and animal models, it has been widely
recognised that b-cell failure is an essential factor
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leading to T2D. This can occur when b-cells fail to
appropriately expand and/or to optimise their function,
ultimately compromising in glucose-stimulated insulin
secretion (GSIS). Animal models of insulin resistance
are excellent models to demonstrate the plasticity of b-
cell mass and provide suitable experimental systems in
which to identify the extracellular signals and molecular
mechanisms behind this compensatory response.
Valuable insights into the key role of b-cell failure in
the pathogenesis of T2D has come from genome-wide
association studies, an important resource to identify
new unexpected susceptibility gene candidates for the
development of T2D [4]. Of interest these studies iden-
tified validated variants associated with insulin-secretory
defects in the general population and showed little if
any relationship to insulin resistance [5-9].
Peroxisome proliferator-activated receptor gamma
(PPARg) is a member of the nuclear receptor superfam-
ily of ligand-activated transcription factors [10] and has
been shown to be involved in many diverse biological
processes, including adipogenesis and glucose and lipid
metabolism. In addition to these roles, it has been
shown that PPARg also exerts an important role in con-
trolling cellular proliferation in different organs includ-
ing pancreatic endocrine tissue. As already
demonstrated, the absence of PPARg specifically in b-
cells cannot fully compensate for the b-cell dysfunction
seen in states of peripheral insulin resistance [11]. In
fact, animals with lack of PPARg had blunted the phy-
siological expansion of b-cell mass in response to high-
fat feeding.
There are important differences between the mechan-
isms controlling the increase of b-cell mass observed
during pregnancy and obesity suggesting certain degree
of etiopathogenic specificity on the mechanisms control-
ling b-cell mass expansion [12-15]. We have recently
shown that b-cell mass adaptation to insulin resistance
failed in the adult POKO mice, an insulin resistant
mouse resulting from the deletion of PPARg2 in an
obese ob/ob background [16]. This impaired b-cell mass
expansion contrasted with the massive expansion
observed in their obese littermate ob/ob mice. Thus, we
rationalised that comparison of ob/ob and POKO mice
islets particularly at early ages could provide some new
insights on early PPARg dependent transcriptional
responses involved in the process of b-cell mass
expansion.
To date, the main approach to identifying global tran-
scriptional changes has been the use of gene expression
microarray platforms in advanced stages of the disease.
Here we focused in early evolutive stages to increase
our chances of identifying novel early events and their
molecular effectors involved in the adaptation of b-cells
to insulin resistance. Our strategy has been to isolate
total RNA samples from islets of 5-week-old female wild
type (WT), PPARg2KO, ob/ob and POKO mice for
large-scale expression profiling. We have used 5-week-
old mice to elucidate pathways and factors underlying
the early islet proliferative response that might have
failed in the POKO mice and that could cause the
inadequate b-cell expansion in this model. Although at
this age metabolic disturbances have not been identified
in islets yet, insulin resistance is already detectable in
ob/ob and POKO mice. In support of this approach we
have shown that defects in proliferation markers can be
detected at 5 weeks of age in POKO islets, well before
alterations in the insulin secretory capacity were evident
[17].
Initially, we have analyzed genes to compare ob/ob
with WT mice. This comparison should identify any
gene regulation in ob/ob mice that may be linked to the
increased expansion of their b-cells. Secondly, we have
compared POKO vs. WT islets. As these two models
have a similar degree of expansion of their b-cells, the
aim was to identify default genes induced during insulin
resistance that were dependent on PPARg2 activity. In
our previous study [17] we have shown that at 16 weeks
of age, despite being more insulin resistant than ob/ob
mice, the b-cell mass of POKO mice remained similar
to that of WT islets. This resulted in POKO mice hav-
ing an inappropriately lower insulin plasma level than
the ob/ob controls at 16 weeks of age [18]. The final
comparison that we have analyzed was between POKO
and ob/ob islets, representing different states of insulin
resistance that could identify PPARg-dependent genes
involved in expansion and function of b-cell.
In this study we have identified genes that are down-
regulated in PPARg-deficient POKO islets that are
related to the proliferation and survival mechanisms
that may facilitate the expansion of b-cell mass under
insulin resistant conditions. We have also identified new
pathways that may contribute to this adaptation such as
immune response, cholesterol biosynthesis, apoptosis
through TGF-b signaling pathway and decreased oxida-
tive phosphorylation. Failure of these adaptive mechan-
isms may contribute to failure of b-cell function in
POKO islets and may be dependent on PPARg expres-
sion and functionality.
Results
Total RNA was extracted from islets obtained from 5-
week-old female WT, PPARg2KO, ob/ob and POKO
mice and used for microarray analysis. The number of
genes differentially expressed amongst the specific
comparisons for an adjusted p-value ≤0.05, (unless
otherwise specified), are shown in table 1 and the
interactions between the diverse comparisons are
shown in Figure 1.
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Differential gene expression between wild type and ob
/ob mice islets
We have previously shown that ob/ob mice have
increased number and size of islets compared with their
WT littermates [17,18], a difference that becomes more
obvious as these mice age and become more metaboli-
cally compromised. Based on these observations, we
hypothesised that the comparison between WT and ob/
ob islets at a young age may identify early initial
changes in islet gene expression associated with or lead-
ing to b-cell mass expansion (Table 2).
As expected the comparison between islets from ob/
ob and WT mice identified many of the genes pre-
viously identified that play a role in b-cell expansion
during states of insulin resistance such as obesity and
pregnancy [15]. These positive controls included genes
involved in proliferation, cell cycle and survival mechan-
isms [19]. For instance, gene expression levels of cyclin
A2, B1, D1 and D3 were significantly increased in islets
from ob/ob compared with WT mice. Conversely
expression of cell division protein kinase 6 (Cdk6) and
Cdk7 were significantly decreased in the ob/ob com-
pared to WT islets. This transcriptional pattern closely
mirrors the pattern observed during the b-cell
hypertrophy typically associated with pregnancy, sug-
gesting these genes are part of a common proliferative
response associated with modulation of b-cell mass in
physiological and pathophysiological states. Our analysis
also confirmed the upregulation of genes encoding for
enzymes involved in regulation of b-cell expansion (IL2-
inducible T-cell kinase (Itk), Tumor necrosis factor
receptor superfamily, member 11b (osteoprotegerin or
Tnfrsf11b), baculoviral IAP repeat containing 5 (Birc5))
and cell cycle regulation (F-box and leucine-rich repeat
protein 14 (Fbxw14), Fbxl21 and F-box protein 27
(Fbxo27)). Globally, these data indicate that at this early
age the ob/ob islets have already activated their prolif-
erative machinery and this data can be considered as a
positive quality control for the experiment.
Differential gene expression between WT and POKO islets
We next compared the gene expression profile between
POKO and WT islets (Table 2). Since the POKO
mouse fails to expand its b-cell mass despite insulin
resistance, we hypothesized that this list may reveal by
default genes induced during insulin resistance that
were dependent on PPARg2 activity. Our first observa-
tion was that POKO and WT islets had a very similar
gene expression profile. In fact the expression of many
of the genes previously shown to be dysregulated in ob/
ob islets were not significantly different in the analysis
comparing POKO and WT islets. This is consistent
with the maintenance of “normal” b-cell mass in POKO
mice that fail to expand. However, through more
detailed analysis, it revealed that despite the inability to
expand their b-cell mass, POKO islets had induction of
some of recognized mediators of b-cell expansion, as
observed during both pregnancy and obesity. These
included Tnfrsf11b, mKi67, Surfactant-associated pro-
tein D (Sftpd) and Free fatty acid receptor 2 (Ffar2).
These genes were increased in both the comparison
between ob/ob vs. WT, and also to a lesser extent in
the comparison between POKO vs. WT. These data
suggested a dysregulation of the homeostatic control of
b-cell mass in POKO islets, and that the ability of
POKO mice to appropriately induce an appropriate
response to a metabolic stress is impaired, with no
increased proliferation and activation of survival
mechanisms in their islets. Globally considered, this
indicates a partial response of PPARg-deficient ob/ob
islets to insulin resistance.
Table 1 Differential expressed genes amongst the specific comparisons
ob/ob vs. WT PPARg2KO vs WT POKO vs. WT ob/ob vs. PPARg2KO POKO vs. ob/ob POKO vs. PPARg2KO
Down 2349 7 (p ≤ 0.2) 51 23 1 (p ≤ 0.3) 81 (p ≤ 0.2)
Up 2532 26 (p ≤ 0.2) 527 30 3 (p ≤ 0.3) 85 (p ≤ 0.2)
Number of differentially expressed genes amongst the specific comparisons for an adjusted p-value ≤0.05 and log FC ≥ 1, unless are specified.
ob/ob vs WT POKO vs WT
PPARγ2KO vs WT
Figure 1 A venn diagram showing relations between
differentially expressed genes. A venn diagram showing relations
between differentially expressed genes (logFC ≥ 1; Adj. P-value
≤0.05) in the comparisons ob/ob vs. WT, POKO vs. WT and
PPARg2KO vs. WT mice.
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Differential gene expression between ob/ob and POKO
mice
We hypothesized that the POKO vs. ob/ob comparison
could identify PPARg2 islet target genes that were dysre-
gulated during the early stages of insulin resistant states
contributing to a lack of b-cell mass expansion. We
have previously shown that at 16 weeks of age POKO
mice have significantly decreased islet number and mass
compared to ob/ob mice and more interestingly, the
number and size of islets in POKO mice resembled the
number and size of the islets of a wild type 16-week-old
mouse [17,18]. Analysis of gene expression by RT-PCR
showed that at 5 weeks of age, there were already some
changes in the expression of specific genes relating to
proliferation (CyclinD1) and b-cell function (Insulin,
MafA, PDX1 and Glut 2), with no evident differences in
insulin secretory defects between POKO and ob/ob [17].
However, differences in gene expression of other genes,
which have been shown at 16 weeks were inconsistent
at this age. Surprisingly the comparison between 5-
week-old ob/ob and POKO islets on microarray data
only identified 3 upregulated genes, (Actin alpha1
(Acta1), Thrombospondin 4 (Thbs4) and Solute carrier
family 5 (sodium/glucose cotransporter) (Slc5a10), and
as expected, down regulation of gene PPARg with an
adjusted p-value ≤0.3 (Table 1). To allow a more
detailed comparison between our models, we performed
pathway analysis using Fatigo and FatiScan tools,
enabling significant multiple comparisons of genes in
significant pathways despite not having differentially
specific expressed genes from these pathways at this
early age.
Dysregulated gene expression pathway analysis in
models with different degree of beta cell expansion
A subsequent post-analysis was performed on the
microarray data from the comparison between 5-week-
old islets in order to identify the main dysregulated
pathways, relating to the expansion of b-cells between
the three genotypes. For this we have used two bioinfor-
matic tools: the Ingenuity Pathway Analysis (IPA) and
gene enrichment test from Babelomics tools (Fatigo),
using an adjusted p value ≤0.05. To allow reliable inter-
pretation of our data we have made the following com-
parisons: ob/ob vs. WT; associated with the normal
adaptation to obesity induced insulin resistance with an
expansion of the b-cell; and POKO vs. WT; associated
with a failure in the adaptive response, with no expan-
sion of b-cell. Using these two lists, we analyzed up-
regulated and down-regulated genes from the compari-
son between ob/ob and WT, which were not regulated
between POKO and WT.
First we analyzed the list of significantly up-regulated
genes in islets from the comparison between ob/ob and
Table 2 Differential gene expression between WT and ob/ob islets and between WT and POKO islets
Comparison WT vs.
ob/ob
Name Symbol Description Log FC Adj p-
value
NM_009828 Ccna2 cyclin A2 (Ccna2), mRNA 1.062995 0.037082104
NM_172301 Ccnb1 cyclin B1 (Ccnb1), mRNA 1.093047367 0.033661413
S78355 Ccnd1 Cyl-1 = cyclin D1 [mice, BALB/c, brain, mRNA, 3737 nt]. 0.814358 0.060937249
NM_007632 Ccnd3 cyclin D3 (Ccnd3), transcript variant 1, mRNA 0.537596 0.081161755
NM_178674 Fbxl21 F-box and leucine-rich repeat protein 21 (Fbxl21), mRNA 1.379136 0.021465994
NM_207238 Fbxo27 F-box protein 27 (Fbxo27), mRNA 1.251021 0.024989279
NM_010583 Itk Mus musculus IL2-inducible T-cellkinase (Itk), mRNA 4.9433924 0.016907267
NM_008764 Tnfrsf11b tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) (Tnfrsf11b), mRNA 2.137707 0.00427033
NM_009689 Birc5 baculoviral IAP repeat-containing 5 (Birc5), transcript variant 1, mRNA 0.749711 0.0488386
NM_015793 Fbxw14 F-box and WD-40 domain protein 14 (Fbxw14), mRNA [NM_015793] 2.053845 0.020165243
NM_009873 Cdk6 cyclin-dependent kinase 6 (Cdk6), mRNA -1.44108 0.011012
AK145759 Cdk7 blastocyst cDNA, RIKEN full-length enriched library, clone:I1C0038J11 product:cyclin-dependent
kinase 7 (homolog of Xenopus MO15 cdk-activating kinase), full insert sequence
-1.18402 0.009851
Comparison WT vs.
POKO
Name Symbol Description Log FC Adj p-
value
NM_008764 Tnfrsf11b tumor necrosis factor receptor superfamily,member 11b (osteoprotegerin)(Tnfrsf11b), mRNA 1.4263697 0.028955326
X82786 mKi67 mRNA for Ki-67. 1.5311213 0.026624778
NM_009160 Sftpd surfactant associated protein D (Sftpd), mRNA 2.10936363 0.04279018
NM_146187 Ffar2 free fatty acid receptor 2 (Ffar2), mRNA 1.371649 0.033601951
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WT mice that were not significantly changed in the
comparison between POKO and WT mice. This was
hypothesised to identify genes that were up regulated
during b-cell expansion during obesity in the case of the
ob/ob, which failed to occur in a PPARg-dependent
model such as the POKO mouse. Up regulated func-
tions scored are based on the number of Network Eligi-
ble molecules they contain the top associated disease
and disorders networks of up regulated genes from IPA
for this first comparison were: immunological disease,
inflammatory disease and inflammatory response. Other
top networks scored for this comparison are presented
in table 3. Cellular Development, and Cellular Function
and Maintenance were identified as the first top mole-
cular and cellular function networks. Cell morphology,
proliferation and development were also in this first
comparison. Similarly, the top five canonical pathways
that they were significant up-regulated included Auto-
immune Thyroid Disease Signalling, Allograft Rejection
Signalling and more importantly Type 1 Diabetes Melli-
tus Signalling (Table 3).
Overall these results demonstrate that b-cell mass
expansion in the context of obesity brings about a
subtle, but coordinated increase in the basal level of a
wide array of genes involved in the inflammatory and
autoimmune response of ob/ob islets that does not
occur in PPARg2-ablated POKO islets. This concept was
supported by the identification of specific molecules
relating to antigen processing and antigen-presenting
signalling such as MHC class II molecules and CD80/86
that were increased in the ob/ob vs. WT comparison
and not the POKO vs. WT. Our analysis has also identi-
fied genes in these pathways such as granzyme B and
perforin 1, with newly recognized roles in inflammation
that have also been implicated in antigen presentation
to cells, and genes such as granulophilin, which is
involved in insulin secretion. Using databases of gen-
ome-wide regulatory module and element predictions
Table 3 Functions and canonical pathways as differentially expressed up-regulated genes in ob/ob vs. WT, with no
significant changes in POKO vs. WT mice
Top Bio Functions
Name p-value # Molecules
Diseases and Disorders
Immunological Disease 7.66E-18 - 3.63E-03 250
Inflammatory Disease 5.95E-15 - 3.60E-03 263
InflammatoryResponse 2.28E-14 - 3.63E-03 144
Skeletal and Muscular Disorders 4.99E-12 - 3.63E-03 255
Connective Tissue Disorders 7.78E-12 - 2.44E-03 175
Molecular and Cellular Functions
Cellular Development 1.45E-17 - 4.37E-03 197
Cellular Function and Maintenance 2.21E-15 - 3.58E-03 103
Cell-To-Cell Signaling and Interaction 9.41E-15 - 4.37E-03 202
Cellular Growth and Proliferation 3.93E-13 - 3.11E-03 173
Cellular Movement 1.94E-09 - 3.78E-03 143
Physiological System Development and Function
Hematological System Development and Function 3.63E-16 - 4.04E-03 189
Hematopoiesis 3.63E-16 - 3.27E-03 112
Tissue Morphology 2.59E-15 - 3.60E-03 124
Cell-mediated Immune Response 1.22E-14 - 3.78E-03 92
Immune Cell Trafficking 2.25E-13 - 3.78E-03 118
Top Canonical Pathways
Name p-value Ratio
Autoimmune Thyroid Disease Signaling 3.06E-13 17/61 (0.279)
Allograft Rejection Signaling 1.49E-12 16/59 (0.271)
Type I Diabetes Mellitus Signaling 4.79E-12 27/119 (0.227)
Graft-versus-Host Disease Signaling 3.57E-10 15/49 (0.306)
B Cell Development 8.43E-10 12/37 (0.324)
Functions and canonical pathways identified by IPA as differentially expressed up regulated genes in islets from ob/ob vs. WT mice (fold change ≥ 1; P ≤ 0.05),
with no significant changes in islets from POKO vs. WT mice.
Note: p value was calculated using the Benjamini-Hochberg method of multiple testing correction. In the case of canonical pathways “Ratio” indicates the
number of differentially expressed genes in a given pathway, divided by total number of genes that make up that pathway.
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(cisRED), we have identified a PPAR conserved sequence
motif in the perforin 1 sequence and by validating
decreased expression of granulophilin by RT-PCR in
PPARg2-ablated mice (Figure 2), it suggests a possible
PPARg dependent pathway.
We have also analysed genes that were down regulated
in ob/ob islets when compared to WT, that were not sig-
nificantly changed in the comparison between POKO
and WT mice (Table 4). Genetic and Developmental
Disorder, Dermatological and Gastrointestinal Disease
were scored as top associated networks in this compari-
son, but organ development, growth and proliferation
were also included in these networks. Significantly down
regulated functions in this comparison were Lipid Meta-
bolism, Small Molecule Biochemistry and Vitamin and
Mineral Metabolism (Table 4). Expression of Tocopherol
(alpha) transfer protein (TTPA), member RAS oncogene
family (RAB27B), Acyl-CoA thioesterase 5 (ACOT5) and
0 1 2 3
ABCA1
MVK
TGFȕ1
FADS3
FADS2
PPARα
PPARδ
Ndufab1
SMAD3
Relative expression /18s
WT
PPARγ2 KO
ob/ob
POKO
p=0.08


Granuphilin
Figure 2 Real time qRT-PCR results form genes to validate microarrays data. Islet gene expression from 5-week-old female WT, ob/ob,
PPARg2KO and POKO mice (n = 8-11 mice per genotype). * p < 0.05 POKO vs. ob/ob.
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Hydroxysteroid (17-beta) dehydrogenase 14 (HSD17B14)
were the most downregulated in ob/ob vs. WT, without
changes between POKO vs. WT. Interestingly, we also
identified a subset of genes from the canonical pathway
of sterol biosynthesis including Mevalonate (diphospho)
decarboxylase (MVD), Farnesyl diphosphate synthase
(FDPS), Prenyldiphosphate synthase, subunit 1 (PDSS1),
Isopentenyl-diphosphate delta isomerase 1 (IDI1), Cyto-
chrome c oxidase 10 (COX10), Mevalonate kinase
(MVK) and Fatty acid desaturase 3 (FADS3) to be signifi-
cantly downregulated in ob/ob vs. WT, without changing
in the comparison between POKO vs. WT (Table 4 and
Figure 2).
We performed a gene enrichment test from Babelo-
mics tools (Fatigo) on our data where significantly up
and down-regulated groups of functionally related genes
were identified from all expressed genes according to
differential expression between the two comparisons
(with higher or lower expression in ob/ob vs. WT but
without changes in POKO vs. WT mice). Among the
1381 up-regulated genes in ob/ob vs. WT we identified
6 significantly (Adj. p-value ≤0.05) overrepresented GO
terms, 11 InterPro and 9 KEGG pathways. Among the
957 down-regulated genes we identified 11 significantly
(Adj. p-value ≤0.05) overrepresented GO terms and 3
KEGG pathways. Subsets of the functional groups are
shown in Table 5, 6 and 7 and were chosen to include
all significant (Adj. p-value ≤0.05) KEGG pathways,
InterPro and all significant overrepresented functional
groups satisfying GO. Confirming our initial data from
IPA, there was an up-regulation of GO terms involved
in the immune response and antigen binding such as
the KEGG pathway positive regulation of immune
response in ob/ob vs. WT, without any change in
POKO vs. WT islets. The down-regulated functional
groups in ob/ob vs. WT without any change in POKO
vs. WT islets were mainly associated with structural
genes and cell-junctions (See Additional file 1 Figure
S1). Consistent with our previous data, we identified
down-regulated cholesterol and sterol biosynthetic
Table 4 Functions and canonical pathways as differentially expressed down-regulated genes in ob/ob vs. WT, with no
significant changes in POKO vs. WT mice
Top Bio Functions
Name p-value # Molecules
Diseases and Disorders
Dermatological Diseases and Conditions 3.01E-05 - 4.21E-02 37
Genetic Disorder 3.01E-05 - 4.21E-02 91
Cancer 9.80E-05 - 4.21E-02 170
Developmental Disorder 6.95E-04 - 4.21E-02 11
Gastrointestinal Disease 1.48E-03 - 4.21E-02 71
Molecular and Cellular Functions
Lipid Metabolism 4.46E-07 - 4.21E-02 50
Small Molecule Biochemistry 4.46E-07 - 4.21E-02 71
Vitamin and Mineral Metabolism 4.46E-07 - 4.21E-02 23
Cell-To-Cell Signaling and Interaction 1.48E-04 - 4.21E-02 63
Cellular Assembly and Organization 1.48E-04 - 4.21E-02 46
Physiological System Development and Function
Tumor Morphology 9.80E-05 - 4.21E-02 22
Hair and Skin Development and Function 1.37E-03 - 4.21E-02 26
Organ Development 1.37E-03 - 4.18E-02 35
Digestive System Development and Function 1.50E-03 - 1.95E-02 11
Organismal Development 1.50E-03 - 4.18E-02 26
Top Canonical Pathways
Name p-value Ratio
Biosynthesis of Steroids 1.96E-04 7/128(0.055)
HER-2 Signaling in Breast Cancer 3.41E-03 9/79 (0.114)
Tight Junction Signaling 9.59E-03 13/167 (0.078)
Fatty Acid Biosynthesis 1.23E-02 3/51 (0.059)
ERK5 Signaling 1.26E-02 7/71 (0.099)
Functions and canonical pathways identified by IPA as differentially expressed down regulated genes in islets from ob/ob vs. WT mice (fold change ≥ 1; P ≤
0.05), with no significant changes in islets from POKO vs. WT mice.
Note: p-value was calculated using the Benjamini-Hochberg method of multiple testing correction. In the case of canonical pathways “Ratio” indicates the
number of differentially expressed genes in a given pathway, divided by total number of genes that make up that pathway.
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process and glutamine transport in the overrepresented
GO terms in the comparison ob/ob vs. WT, without any
significant difference in POKO vs. WT mice (Table 8
and Additional file 1 Figure S2).
Functional profiling of differentially expressed genes in
POKO mice that may contribute towards failure to
expand beta cell mass
We performed FatiScan analysis in the comparison
between POKO and ob/ob islets obtained from our
microarray. This FatiScan analysis highlights the value
of using functional analysis, which incorporates all
experimental data rather than limiting interpretation to
those genes that rank among the highly differentially
expressed. Using the FatiScan tool, 616 gene ontology
groups, 85 InterPro, 67 KEGG pathways, 7 Biocarta, and
3 JasparTBS were observed to be significantly (adj. p
value ≤ 0.05) overrepresented in islets from POKO rela-
tive to the ob/ob mice. There was a substantial overlap
of genes within these identified functional groups result-
ing in the overrepresentation of a large number of func-
tionally similar gene ontology groups. Therefore only
the highly expressed groups have been shown in tables.
Initially, an overrepresentation of genes related to bio-
logical processes such as neutral lipid catabolic process,
lipid glycosilation, collagen biosynthesis process and reg-
ulation of actin filament length were identified. Analysis
from FatiScan also identified genes related to mitochon-
drial outer and inner membrane translocase complex
and fibrillar collagen in the cellular component group
and profilin, lipoic acid and IgG binding in the molecu-
lar function group. Other molecular functions associated
with highly expressed genes in POKO islets compared
with ob/ob were RPTP-like protein binding, platelet-
derived growth factor binding and nucleocytoplasmic
transporter activity. Genes from terms associated to
Chaperonin TCP-1, Mob/phocein, hexokinase were
identified as domains in InterPro.
The most significant KEGG pathways identified in the
FatiScan functional analysis of genes with higher expres-
sion in POKO compared to ob/ob islets were the olfac-
tory transduction and spliceosome (Table 9). Although
no significant differences in singular genes were
detected between both genotypes, this analysis found
that there was increased expression of pathways with
genes related to the formation of cellular junctions
between cells as regulation of actin cytoskeleton, tight,
adherence and gap junction. Pathways identified with
increased gene expression in POKO compared to ob/ob
islets also included terpenoid backbone, glutathione
Table 5 KEGG significant terms up-regulated in ob/ob vs. WT, without significant changes in POKO vs. WT mice
Term Name Term size Odds ratio log Adj. p-value
mmu00604 Glycosphingolipid biosybthesis 21 1.86 2.43E-02
mmu04940 Type 1 diabetes 54 1.83 2.96E-05
mmu05330 Allograt rejection 48 1.79 1.24E-04
mmu05332 Graft-verus host disease 50 1.74 1.63E-04
mmu05320 Autoinmune thyroid disease 63 1.71 3.08E-05
mmu04514 Cell adhesion molecules 141 1.65 2.05E-10
mmu05416 Viral myocarditis 80 1.23 5.78E-03
mmu04730 Long term depresion 74 1.14 2.51E-02
mmu04270 Vascular smooth muscle contact 126 1.12 1.43E-03
KEGG significant terms up-regulated in islets from ob/ob vs. WT mice (adjusted p-value ≤ 0.05), without significant changes in islets from POKO vs. WT mice.
Table 6 InterPro significant terms up-regulated in ob/ob vs. WT, without significant changes in POKO vs. WT mice
Term Name Term size Odds ratio log Adj. pvalue
IPR006116 2-5-oligoadenylate synthetase, ubiquitin-like region (IPR006116) 14 2.49 1.88E-02
IPR000342 Regulator of G protein signalling (IPR000342) 36 1.68 3.76E-02
IPR003597 Immunoglobulin C1-set (IPR003597) 93 1.62 5.28E-06
IPR006907 Protein of unknown function DUF622 (IPR006907) 73 1.51 1.05E-03
IPR003596 Immunoglobulin V-set, subgroup (IPR003596) 276 1.24 8.33E-09
IPR013151 Immunoglobulin (IPR013151) 364 1.22 3.35E-11
IPR003006 Immunoglobulin/major histocompatibility complex, conserved site (IPR003006) 90 1.17 4.29E-02
IPR007110 Immunoglobulin-like (IPR007110) 488 1.17 3.81E-13
IPR013106 Immunoglobulin V-set (IPR013106) 330 1.15 1.25E-08
IPR003599 Immunoglobulin subtype (IPR003599) 441 1.01 2.36E-08
IPR003598 Immunoglobulin subtype 2 (IPR003598) 371 0.89 7.22E-05
InterPro significant terms up-regulated in islets from ob/ob vs. WT mice (adjusted p-value ≤ 0.05), without significant changes in islets from POKO vs. WT mice.
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metabolism, TGF-b signalling and steroid biosynthesis.
Closer inspection of TGF-b1 and SMAD3 in 5-week-old
POKO mice by RT-PCR surprisingly showed no signifi-
cant increase in mRNA expression when compared to
ob/ob mice (Figure 2). However we found increased sig-
nificant immunostaining for TGF-b in POKO pancreas
sections at 16 weeks of age, starting to be present at 4
weeks in POKO mice (Figure 3).
Pathways associated to genes with lower expression in
POKO compared to ob/ob islets were also identified by
Fatiscan (Table 10 Figure 2) such as those relating to
oxidative phosphorylation, sulphur metabolism reduc-
tion and fixation, mature onset diabetes in the young,
ATP-binding cassette (ABC) transporters and Type 1
and Type 2 diabetes. These results support the data
obtained in our previous analysis between both the ob/
ob vs. WT and POKO vs. WT comparisons. Further-
more, we have also verified significantly decreased
expression of ABCA1 and an isoform of NADH dehy-
drogenase (Ndufab1) in the islets of 5-week-old POKO
compared with ob/ob mice by RT-PCR (Figure 2).
Carbohydrate responsive element-binding protein
(Chrebp), casein kinase 1 (ck1) and insulin-like growth
factor type 1 receptor (igfr1) pathways were the three
highly expressed in Biocarta associated to genes with
higher expression in POKO compared with ob/ob islets
(data not shown).
FastiScan analysis identified 3 JasparTBS to be signifi-
cantly (adj. p-value ≤ 0.05) overrepresented in islets
from POKO relative to the ob/ob mice. The list of
genes regulated by the transcription factors Pax2 and
Arnt:Ahr were significantly expressed in POKO com-
pared with ob/ob islets, while genes regulated by
HOXA5 were down regulated and overrepresented in
POKO islets (Table 11).
Dysregulation of genes dependent on PPAR in POKO and
ob/ob islets
One of the pathways we found to be altered in FatiScan
analysis between POKO vs. ob/ob was the PPAR path-
way (Table 9). The expression of PPAR alpha and total
PPAR gamma were decreased in the islets of POKO
Table 7 GO significant terms up-regulated in ob/ob vs. WT, without significant changes in POKO vs. WT mice
Name Term size Odds ratio log Adj. pvalue
GO molecular function
antigen binding (GO:0003823) 23 2.87 1.136E-06
GO cellular component
cell surface (GO:0009986) 365 0.91 1.48E-07
external side of plasma membrane (GO:0009897) 190 1.41 2.38E-11
guanylate cyclase complex, soluble (GO:0008074) 5 1.8 6.95E-07
GO biological process
immune response (GO:0006955) 599 0.83 7.288E-06
peptide hormone processing (GO:0016486) 13 2.93 4.08E-003
GO significant terms up-regulated in islets from ob/ob vs. WT mice (adjusted p-value ≤ 0.05), without significant changes in islets from POKO vs. WT mice.
Table 8 GO significant terms down-regulated in ob/ob vs. WT, without significant changes in POKO vs. WT mice
Name Term size Odds ratio log Adj. pvalue
GO molecular function
L-glutamine transmembrane transporter activity (GO:0015186) 5 4.55 1.27E-002
GO cellular component
desmosome (GO:0030057) 24 2.47 2.39E-004
apical junction complex (GO:0043296) 132 1.82 1.17E-009
apicolateral plasma membrane (GO:0016327) 134 1.8 1.17E-009
tight junction (GO:0005923) 102 1.7 3.21E-006
cell-cell junction (GO:0005911) 219 1.4 2.54E-007
cell junction (GO:0030054) 540 0.88 1.57E-005
GO biological process
cholesterol biosynthetic process (GO:0006695) 30 2.47 4.76E-004
sterol biosynthetic process (GO:0016126) 37 2.17 2.13E-003
tongue development (GO:0043586) 12 3.16 3.09E-003
glutamine transport (GO:0006868) 5 4.55 9,11E-003
GO significant terms down-regulated in islets from ob/ob vs. WT mice (adjusted p-value ≤ 0.05), without significant changes in islets from POKO vs. WT mice.
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compared with ob/ob mice (Figure 2); however the
expression of PPAR beta/delta were increased (Figure 2
and Additional file 1 Table S1). Furthermore, the
expression of the three isoforms of the nuclear receptor
Retinoic X receptor (RXR alpha, beta and gamma), het-
erodimers of PPARs, were differentially altered depend-
ing on the isoform as shown in the table. Most of the
pathways analysed had increased or decreased expres-
sion of PPAR target genes as shown in Additional file 1
Table S1. However, gene expression of PPAR target
genes involved in lipogenesis (SCD1, ME1, FADS2) and
in cholesterol metabolism (CYP7A1, CYP8B1, LXRa and
CYP27) were increased in POKO compared to ob/ob
islets (Figure 2). Conversely, PPAR target genes involved
in fatty acid oxidation (Ehhadh, Acaa1b, SCP2, Acox1,
CPT1a, CPT1c and CPT2) were decreased suggesting
these genes could be regulated by the PPARg2 isoform,
a pattern also observed with genes involved in adipocyte
differentiation (Perilipin, aP2, adipoq, MMP-1) or gluco-
neogenesis (PEPCK, GyK, AQP7).
Genome Wide candidate genes and early transcriptional
response in pancreatic beta cells
Recent genome-wide association studies have provided
an important resource for furthering our understanding
of type 2 diabetes disease mechanisms [5,9]. These pub-
lished variants were all associated with insulin-secretory
defects in the general population and show little if any
relationship to insulin resistance. We have checked
these genes in both our comparisons (See additional file
1 Figure S3). Although expression of Slc30A8 was not
altered in the two comparisons in our microarray data,
we found that expression of Slc30A8 detected by RT-
PCR was decreased in islets from POKO compared to
ob/ob mice and in islets from PPARg2KO compared to
WT mice. Furthermore, using NSITE/Recognition of
Regulatory motifs tool we found a PPAR conserved
sequence motif in this gene suggesting this gene has a
dependency on PPARg.
We also checked expression of NR4A3 (also called
Neuron-derived orphan receptor (Nor) 1) by RT-PCR in
our models. This is a novel candidate gene for b-cell
function, which was not covered by the SNP arrays of
the recent genome-wide association studies for type 2
diabetes mellitus [20]. Here we found significantly
increased expression of NR4A3 in ob/ob and POKO
islets when compared with WT and PPARg2KO islets,
but no significant differences between the ob/ob and
POKO islets (See Additional file 1 Figure S3).
Recent studies have shown that the Notch-regulated
transcription factor neurogenin 3 (Ngn3) is critical for
Table 9 KEGG significant terms up-regulated in POKO vs.
ob/ob mice
ID Term
mmu04740 Olfactory transduction
mmu03040 Spliceosome
mmu04810 Regulation of actin cytoskeleton
mmu04530 Tight junction
mmu04520 Adherens junction
mmu03050 Proteasome
mmu03010 Ribosome
mmu05219 Bladder cancer
mmu04512 ECM-receptor interaction
mmu05200 Pathways in cancer
mmu04670 Leukocyte transendothelial migration
mmu04115 p53 signaling pathway
mmu03020 RNA polymerase
mmu04020 Calcium signaling pathway
mmu00270 Cysteine and methionine metabolism
mmu00260 Glycine, serine and threonine metabolism
mmu00830 Retinol metabolism
mmu00240 Pyrimidine metabolism
mmu04510 Focal adhesion
mmu00900 Terpenoid backbone biosynthesis
mmu00100 Steroid biosynthesis
mmu00450 Selenocompound metabolism
mmu00480 Glutathione metabolism
mmu04012 ErbB signaling pathway
mmu04360 Axon guidance
mmu03420 Nucleotide excision repair
mmu04621 NOD-like receptor signaling pathway
mmu04144 Endocytosis
mmu04540 Gap junction
mmu00330 Arginine and proline metabolism
mmu04010 MAPK signaling pathway
mmu04062 Chemokine signaling pathway
mmu04110 Cell cycle
mmu00970 Aminoacyl-tRNA biosynthesis
mmu04350 TGF-beta signaling pathway
mmu00230 Purine metabolism
mmu03030 DNA replication
mmu00250 Alanine, aspartate and glutamate metabolism
mmu00561 Glycerolipid metabolism
mmu04060 Cytokine-cytokine receptor interaction
mmu00520 Amino sugar and nucleotide sugar metabolism
mmu00290 Valine, leucine and isoleucine biosynthesis
mmu00052 Galactose metabolism
mmu00040 Pentose and glucuronate interconversions
mmu03018 RNA degradation
mmu03320 PPAR signaling pathway
KEGG significant terms up-regulated in islets from POKO vs. ob/ob mice
(adjusted p-value ≤ 0.05)
Vivas et al. BMC Medical Genomics 2011, 4:86
http://www.biomedcentral.com/1755-8794/4/86
Page 10 of 17
the development of endocrine cells of islets [21]. Ngn3
was increased in islets from ob/ob and POKO mice
compared with those from PPARg2KO and WT, but
with no significant differences between the former geno-
types. From the current GWAS and metaanalysis in
Europeans associated to adiposity loci [22], we identified
increased NEGR1 expression in our microarray data
between ob/ob and WT islets and lower expression in
POKO when compared to ob/ob islets after analysis by
RT-PCR.
Discussion
In this study we have used a gene expression microarray
and a subsequent bioinformatic approach to identify new
molecular mechanisms and pathways implicated in the
expansion of pancreatic b-cells in the context of insulin
WT PPAγ2KO ob/ob POKO
4 weeks
16 weeks
Figure 3 Representative photomicrographs for TGF-ß immunostaining in pancreas sections at different age. TGF-b immunostaining in
pancreas sections from WT, ob/ob, PPARg2KO and POKO mice at 4 and 16 weeks (n = 3-4 mice per genotype).
Table 10 KEGG significant down-regulated in POKO vs.
ob/ob mice
ID Term
mmu00190 Oxidative phosphorylation
mmu05016 Huntington’s disease
mmu05012 Parkinson’s disease
mmu04142 Lysosome
mmu04270 Vascular smooth muscle contraction
mmu04730 Long-term depression
mmu04940 Type I diabetes mellitus
mmu02010 ABC transporters
mmu00510 N-Glycan biosynthesis
mmu04612 Antigen processing and presentation
mmu04720 Long-term potentiation
mmu05330 Allograft rejection
mmu04260 Cardiac muscle contraction
mmu04070 Phosphatidylinositol signaling system
mmu00920 Sulfur metabolism
mmu05320 Autoimmune thyroid disease
mmu04912 GnRH signaling pathway
mmu04930 Type II diabetes mellitus
mmu04914 Progesterone-mediated oocyte maturation
mmu04950 Maturity onset diabetes of the young
KEGG significant terms down-regulated in islets from POKO vs. ob/ob mice
(adjusted p-value ≤ 0.05).
Table 11 Jaspar TFBS significant terms down-regulated in
POKO vs. ob/ob mice
Term Term size Odds ratio log Adj pvalue
Pax2 298 0.54 3.20E-02
Arnt::Ahr 456 0.47 3.20E-02
HOXA5 168 -0.74 2.88E-02
Jaspar Transcription Factor Binding Site (TFBS) significant terms down-
regulated in islets from POKO vs. ob/ob mice (adjusted p-value ≤ 0.05).
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resistance. Using this technique and bioinformatic analysis
we have investigated: 1) the overrepresentation of genes
related to b-cell expansion under situations of insulin
resistance in islets, 2) the genes differentially expressed in
insulin resistant islets with and without the capacity of b-
cell to expand, and 3) the overrepresentation of functional
groups of genes differentially expressed previously to nor-
mal o defective expansion of b-cell mass.
We first examined genes that were upregulated in the
islets of ob/ob compared to WT mice, expecting to
identify pathways relevant to b-cell mass expansion for
future comparison with the POKO mouse which is
unable to expand its islets. We found that, at the age of
5 weeks, the ob/ob islets already exhibit induction of
several pathways relating to cell proliferation and survi-
val mechanisms. This response was not observed in
POKO islets suggesting that these regulatory mechan-
isms are activated very early on before severe metabolic
stress has developed, and that a failure to initiate these
pathways is effectively contributing to the failure of the
homeostatic control of b-cell mass in POKO islets. Spe-
cifically, POKO islets did not show the same induction
of cyclin A2, B1, D1 and D3 observed in ob/ob islets,
where in addition to their role in cell cycle progression,
new data has revealed an emerging role of D-type
cyclins in transcriptional regulation and cellular differ-
entiation processes. There is also evidence from studies
in 3T3-L1 cells that cyclin D3 acts as a ligand-depen-
dent PPARg coactivator and that its expression is
increased throughout the adipocyte differentiation pro-
cess [23]. Our results could therefore suggest that regu-
lation of cyclinD3 is at least partly dependent on PPARg
which may be of relevance in the proliferative mechan-
isms of b-cell mass. Other universal genes previously
shown to be increased during the expansion of the b-
cell during obesity or pregnancy such as Birc5, Igf1r and
Rasgrp1 also failed to increase in PPARg deficient ob/ob
islets (POKO vs. WT) further suggesting an inability of
POKO islets to proliferate at a young age.
We were interested in identifying a putative molecular
mechanism that could induce the pancreatic islet dys-
function in POKO mice. Our experimental design
allowed the identification of pathways associated with
the normal adaptation of islets to obesity induced insu-
lin resistance (comparison ob/ob vs. WT) and pathways
associated with failure in this response (comparison
POKO vs. WT). We have identified genes associated
with canonical pathways of Autoimmune Thyroid Dis-
ease Signalling, Allograft Rejection Signalling and Type
1 Diabetes Mellitus Signalling are upregulated in ob/ob
vs. WT islets. This was associated with a significant
increase of genetic programmes related to inflammatory
disease, inflammatory response and immunological dis-
ease. It is well established that inflammation and fibrosis
are processes preceding the deterioration of pancreatic
islet structure. Molecules from MHCII (HLA-D, HLA-
A, HLA-B) and other molecules such as CD80/86,
which are involved in the antigen presentation signalling
were increased in ob/ob relative to WT islets, with no
significant changes in the islets of POKO vs. WT, sug-
gesting that their involvement in remodelling is linked
to b-cell mass expansion. As these pathways are acti-
vated in ob/ob islets and not in POKO islets, and that
this is occurring very early before ob/ob islets fail, we
speculate that this immune and inflammatory response
may in fact be a physiological response, initiating or
enabling a mechanism of remodelling or adaptation in
order for the b-cell mass to expand. Thus it is conceiva-
ble that these changes are part of an adaptive response
required under metabolic stress as occurs in ob/ob
mice, possibly involving signalling via PPARg.
Our FatiScan analysis showed that TGF-b/Smad sig-
naling pathway was significantly increased in POKO
compared to ob/ob islets, which is supported by
increased pancreatic staining of TGF-b in POKO islets
at 4 and 16 weeks of age. It has already been shown in
other organs such as kidney that stimulation of fibrotic
processes could be mediated, at least in part, by a
down-regulation of PPARg that can favour an up-regula-
tion of the TGF-b/Smad signalling pathway [24,25].
Genes such as TGF-b1, its receptors type I and II and
SMAD2/3/4, also implicated in apoptosis and cell cycle
arrest through this pathway were increased in POKO
islets compared to ob/ob islets, suggesting that specific
profibrotic and apoptotic genes could also be involved
in the failure of b-cell expansion in POKO islets.
Two genes, perforin 1 and granzyme B which are
required for the direct recognition of the cells [26] were
also up regulated in our ob/ob vs. WT comparison. The
dominant role of the perforin/granzyme pathway in b-cell
destruction in type 1 diabetes and allogeneic islet graft
rejection makes this pathway an important target for
future therapies for type 1 diabetes. However our results
and the suggested new role of these molecules in inflam-
mation also suggests that they could be new targets for
treatments of type 2 diabetes, as part of their role includes
the adaptation of the b-cell to insulin resistance. Indeed
they could contribute to the remodelling mechanisms
enabling the necessary expansion of the pancreatic b-cell
by controlling apoptosis in a PPARg dependent pathway.
Supporting this idea, we have found that the perforin pro-
moter has a PPAR response element and that POKO islets
lack this immune response, further supporting its role
facilitating the remodelling adaptation in response to insu-
lin resistance. Globally considered our data indicate that
PPARg-ablated islets (POKO) may have decreased capacity
for remodelling and an exacerbated proapoptotic response
ultimately leading to their failure.
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Besides an increased b-cell mass during the adaptation
to insulin resistance, the most immediate response is
the optimisation of the insulin secretion. The data from
this study showed that cholesterol-induced impairment
of b-cell function could occur in POKO islets as hap-
pens in other models [27]. It has already been shown
that Ldlr-/- knockout mice with b-cell-specific ATP-
binding cassette transporter A1 (ABCA1) deficiency
showed increased islet cholesterol content and b-cell
dysfunction, suggesting that cholesterol efflux through
ABCA1 is a critical regulator of islet cholesterol content
and b-cell function [28]. Functional analysis using FatiS-
can and our RT-PCR results revealed increased expres-
sion of genes related to cholesterol and sterol
biosynthesis and decreased expression of ATP-binding
cassette (ABC) transporters in POKO compared with
ob/ob islets. Also rosiglitazone, an activator of the per-
oxisome proliferator-activated receptor-gamma, requires
b-cell ABAC1 for its beneficial effects on glucose toler-
ance. It has been suggested that elevated b-cell choles-
terol levels may impair insulin secretion by promoting
the dimerisation of neuronal NO synthase (nNOS),
which downregulates glucokinase (GK), thus impairing
glucose sensing. This will agree with our previous obser-
vation showing that GK is downregulated in POKO
compared with ob/ob islets [17]. Moreover, it has been
suggested that cholesterol also inhibits steps in insulin
exocytosis and that ABCA1 could have other indepen-
dent effects on insulin secretion. Here we show that
granulophilin is downregulated in POKO islets and its
expression depends on PPARg similarly to GK. Thus we
suggest that PPARg could play a main role determining
the cholesterol flux and its toxicity on the islet insulin
secretion machinery under insulin resistance conditions.
Another pathway down regulated in POKO in com-
parison to ob/ob islets was oxidative phosphorylation.
Different isoforms of Cytochrome c oxidase and NADH
dehydrogenase were downregulated in POKO compared
to ob/ob islets suggesting impaired complexes of the
mitochondrial oxidative phosphorylation system in
POKO islets could contribute to the failure of their
islets. It has been shown recently in human islets and
cell lines [29], that increased levels of nitrogen species
may interact with the insulin exocitosis mechanism.
From our previous data, we did not observe increased
levels of ROS in POKO mice at this age; however nitro-
gen species under pathophysiological conditions such as
chronic hyperglycemia could result in insulin secretion
dysfunction in POKO islets.
Actin cytoskeleton remodelling is known to be
involved in glucose-stimulated insulin secretion (GSIS).
Cell-cell contacts mediated by intercellular junctions are
crucial for proper insulin secretion in the endocrine
pancreas. FatiScan analysis found that the tight junction,
adherens junction and focal adhesion pathways were
increased in POKO compared to ob/ob islets. In fact
expression of Actin 1 alpha, which is involved in focal
adhesion, was increased in POKO islets. Of note activa-
tion of actin cytoskeleton could result in increased fibro-
sis in the islets of POKO mice in a process facilitated by
TGF-b/Smad activation as has been similarly shown in
liver fibrosis [30].
Genome-wide association studies (GWAS) have had
success in identifying loci that are involved in common
diseases such us diabetes and interestingly some locus
were linked specifically with T2D. Mouse models offer a
good tool to help to take data from GWAS studies
further investigating the function of associated genes in
vivo. We further investigated some of these T2D sus-
ceptibility loci identified thorough GWAS in our mod-
els. We found only significant dowregulation in GK and
SLC30A8 in POKO in comparison to ob/ob islets, both
dependent on PPARg expression. Specific b-cell inactiva-
tion of SLC30A8 in mouse results in glucose intolerance
[31] and recently published meta-analysis results
revealed a significant association between the
rs13266634 C/T polymorphism of SLC30A8 and T2DM
and IGT [32]. Our results suggest that SLC30A8 might
therefore have a role in expansion of the b-cell and ben-
efit from PPARg agonists in the treatment of type 2
diabetes.
Conclusions
Using transcriptome tools and mouse models of insulin
resistance, in this study we show: a) that mechanisms of
proliferation and survival signals were downregulated in
POKO islets from an early age, b) we also identified
new pathways that could be involved in the adaptation
of the b-cell to insulin resistance during obesity and
that they are defective in PPARg-deficient ob/ob islets.
Our results indicate that early stages of b-cell mass
expansion are associated with activation of an inflamma-
tory immune response that could facilitate the necessary
remodeling while preventing activation of an apoptotic
cascade. Other potential relevant pathogenic mechan-
isms modulating b-cell mass include cholesterol toxicity,
TGF-b/Smad pathway-induced apoptosis/fibrosis and
defective oxidative phosphorylation. As the pathways
identified in our POKO islets are involved in the failure
of b-cell function, our results indicate an important role
of PPARg in islets, modulating the adaptive response of
b-cell mass to increased metabolic demands imposed by
obesity and insulin resistance.
Methods
Animal care
Animals were housed in a temperature-controlled room
(20-22 8C) with 12-h light/dark cycles. Food and water
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were available ad libitum unless noted. All animal proto-
cols used in this study were approved by the UK Home
Office and the University of Cambridge and by Ethical
and Veterinary committees of Rey Juan Carlos Univer-
sity in Spain.
Isolation and culture of pancreatic islets
The pancreas was injected, though the bile duct, with
cold Hank’s solution containing 0.4% (w/v) collagenase
P (Roche Biochemicals). The pancreas was removed,
digested for 8 minutes, and islets were collected by hand
picking. Isolated islets were cultured overnight in cell
medium (RPMI 1640 with 10% FBS, and 100 UI/ml
penicillin, 100 μg/ml streptomycin), at 37°C, in 5% CO2
in air. For RNA extraction, islets were used on the day
after isolation.
RNA isolation and purification
An average of 25-50 islets were used per sample and
total RNA was extracted according to the manufac-
turer’s instructions. Each sample was purified using the
RNeasy® Mini kit (Qiagen Ltd, Crawley, UK). RNA was
quantified using a NanoDrop® ND1000 spectrophot-
ometer V 3.5.2 (NanoDrop Technologies, Wilmington,
DE). RNA quality was subsequently assessed using the
28S:18S ratio running the samples on a denaturing agar-
ose gel. The 2:1 ratio (28S:18S) indicated that the RNA
was intact.
Sample labelling
One-Color Microarray-Based Gene Expression Analysis
Protocol (Agilent Technologies, Palo Alto, CA, USA)
was used to amplify and label RNA. A pool of 3-4 mice
were used per each microarray and 3 microarrays were
used per each genotype. Briefly, 400 ng of total RNA
from WT, PPARg2KO, ob/ob and POKO mice, were
reverse transcribed using T7 promoter primer and the
Moloney murine leukemia virus (MMLV) reverse tran-
scriptase. cDNA was then converted to anti-sense RNA
(aRNA) by using T7 RNA polymerase that amplifies tar-
get material and incorporates cyanine 3 (Cy3)-labeled
CTP simultaneously.
Sample hybridization and image analysis
Samples were hybridized to a Whole Mouse Genome
Microarray 4x44K (G4122F, Agilent Technologies). 1.65
micrograms of Cy3-labeled aRNA were hybridized for
17 hours at 65°C in an Agilent hybridization oven
(G2545A, Agilent Technologies) set to 10 rpm in a final
concentration of 1x GEx Hybridization Buffer HI-RPM
(Agilent Technologies). Arrays were washed and dried
out using a centrifuge according to manufacturer’s
instructions (One-Color Microarray-Based Gene Expres-
sion Analysis, Agilent Technologies). Arrays were
scanned at 5 mm resolution on an Agilent DNA Micro-
array Scanner (G2565BA, Agilent Technologies) using
the default settings for 4x44k format one-color arrays.
Images provided by the scanner were analyzed using
Feature Extraction software v10.1.1.1 (Agilent
Technologies).
Quality control
Based on statistical outliers criteria implemented in the
Bioconductor package “ArrayQualityMetrics” there were
no statistical outliers in terms of MA plots, dendrogram
or boxplots.
Statistical analysis
For the normalization, Agilent Processed Signal (Agilent
Feature Extraction Software) was standardized across
arrays using quantile normalization [33].
Differential gene expression was carried out using the
limma [34] package from Bioconductor. This approach
fits a linear model to all data considering as fixed effect
the type of mice and using the array as blocking vari-
able. Limma calculates moderated t-statistics, adding to
the error term some information on the variance of all
genes, solving the typical microarray problem of small
sample size (2 in one of the experimental groups). Mul-
tiple testing adjustment of p-values was done according
to Benjamini and Hochberg methodology [35].
The microarrays data of this study have been depos-
ited in the Gene Expression Omnibus database under
accession number GSE33647.
Ingenuity Pathway Analysis
Functional and Canonical Pathway analyses of specific
gene datasets were generated through the use of Ingenu-
ity Pathway Analysis (Ingenuity Systems®, http://www.
ingenuity.com).
The Functional analysis identified functions and/or
diseases that were most significant to the dataset. Genes
from the dataset that were associated with biological
functions and/or diseases in the Ingenuity knowledge
base were considered for the analysis. B-H Multiple
Testing Correction p-value test was used to calculate a
p-value determining the probability that each biological
function and/or disease assigned to the data set is due
to chance alone.
Genes associated with a canonical pathway in the
Ingenuity knowledge database were considered for the
analysis. The significance of the association between the
dataset and the canonical pathway was measured in two
ways: 1) A ratio of the number of genes from the data-
set that map to the pathway divided by the total number
of molecules that exist in the canonical pathway is dis-
played. 2) B-H Multiple Testing Correction p-value test
was used to calculate a p-value determining the
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probability that the association between the genes in the
dataset and the canonical pathway is explained by
chance alone. IPA identified significant networks, top
functions and canonical pathways associated with the
differentially expressed genes for each comparison
analyzed.
FatiGO and FatiScan analysis
Enrichment analysis and gene set analysis was carried
out for the Gene Ontology terms, InterPro terms and
for the KEGG Pathways using FatiGO [36] and FatiScan
[37] integrated in Babelomics suite [38].
FatiGO is a procedure to extract several functional
terms as Gene Ontology (GO) terms, InterPro annota-
tion or KEGG Pathways that are significantly over-or
under-represented in sets of genes within the context of
a genome-scale experiment. This resource is used to
detect relevant functional terms for a group of genes
with respect to a set of genes of reference (typically the
rest of genes). The terms are considered to be relevant
by the application of a Fisher’s exact test that considers
the multiple-testing nature of the statistical contrast
performed.
FatiScan is a gene set analysis that detects significantly
up-or down-regulated blocks of functionally related
genes in lists of genes ordered by differential expression.
FatiScan can search blocks of genes that are functionally
related by different criteria such as gene ontology terms,
Kyoto Encyclopedia of Genes and Genomes pathways,
and others. The core of the method proposed is based
on an algorithm to test whether a set of genes, labeled
with terms (biological information), contain significant
enrichments on one or several of these terms with
respect to another set of genes of reference. FatiScan
uses a Fisher’s exact test for 2 × 2 contingency tables
for comparing two groups of genes and extracting a list
of GO terms whose distribution among the groups is
significantly different. Given that many GO terms are
simultaneously tested, the results of the test are cor-
rected for multiple testing to obtain an adjusted p-value.
FatiScan returns adjusted p-values based on False Dis-
covery Rate (FDR) method [39,40].
GO and InterPro annotation for the genes in the
microarray where taken from Ensembl 56 release and
KEGG Pathways from the KEGG web page.
RNA preparation and real-time quantitative PCR for
validation of the microarray
Selected cDNA samples (n = 8-11) were quantified by
real time quantitative PCR (qRT-PCR). Total RNA was
isolated from islets samples according to the manufac-
turer’s instructions following same protocols used for
microarray RNA samples. Complimentary DNA was
generated from 500 ng of RNA using M-MLV reverse
transcriptase and master mix (Promega) in a 20 μl reac-
tion with 2.5 mM MgCl2, 1.25 mM dNTPs and 5 μg/ml
random hexamers at 37°C for 1 hour. cDNA was diluted
75 fold and 5 μl of diluted cDNA was used in a 12 μl
real time PCR reaction using TaqMan primers and
probes or SYBR green reagent (Applied Biosystems)
according to manufacturers instructions. Reactions were
run in duplicate for each sample and quantified in the
ABI Prism 7900 sequence detection system (Applied
Biosystems). Data was normalised to 18s rRNA. Primer
sequences are shown in Additional file 1 Table S2.
Immunohistochemistry of TGF-beta
Fixed tissue sections (4 μm) were dehydrated by graded
ethanol’s and xylene, and then embedded in paraffin (2-
3 sections per animal, 3-4 animal per group). The sec-
tions were deparaffinized and rehydrated. Sections were
incubated with anti-TGF-b(SantaCruz Biotechnology,
INC.). Sections were incubated with a biotinylated anti-
IgG (Vector Laboratories) and incubated with the avi-
din-biotin-peroxidase complex (Vector Laboratories). 3,
3’-diaminobenzidine (DAB) substrate (Sigma-Aldrich®)
was used as the chromogen. Some samples were incu-
bated without primary antibody as negative controls.
The stained sections were imaged with a light micro-
scope Zeiss Standard 25.
Additional material
Additional file 1: Figure S1 - GO Cellular Component significant
terms. GO Cellular Component significant terms (adjusted p-value ≤
0.05) down-regulated in ob/ob vs. WT, without significant changes in
POKO vs. WT. Figure S2 - GO Biological Process significant terms. GO
Biological Process significant terms (adjusted p-value ≤ 0.05) down-
regulated in ob/ob vs. WT, without significant changes in POKO vs. WT.
Figure S3 - Real time qRT-PCR results form genes from GWAS
studies to validate microarrays data. Islet gene expression from 5-
week-old female WT, ob/ob, PPARg2KO and POKO mice (n = 8-11 mice
per genotype). * p < 0.05 POKO vs. ob/ob. Table S1 - PPAR signalling
pathway in POKO vs. ob/ob mice. Genes from PPAR signalling
pathway (adjusted p-value ≤ 0.05) in islets from POKO vs. ob/ob mice.
Table S2 - Table of primers and probes sequences used in RT-PCR
validation. Sequences of primers and probes (Syber-Green and Taqman)
used in RT-PCR validation.
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